Horizon 1 1 17 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES Diabetes and Metabolism 385-391 Metformin Prediabetes Cardiometabolic risk factors Clinical trial 2009 PAR00004369 ENG Diabetes and Metabolism 1262-3636 ISI:000272208900006 5 10.1016/j.diabet.2009.03.005 https://www.documentation.ird.fr/hor/PAR00004369 https://www.documentation.ird.fr/intranet/publi/depot/2015-10-26/010065780.pdf 35 Horizon (IRD) Aim. - Metformin has recently been considered as a possible pharmacological complement to lifestyle measures for preventing type 2 diabetes in high-risk subjects. However, little is known of its effects on metabolic and cardiovascular risk factors in non-diabetic subjects. Methods. - The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin. We compared the changes (1-year minus baseline) in cardiometabolic risk factors between treatment groups in two subsets of trial subjects: those with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (n = 101); and those who fulfilled the inclusion criteria of the Diabetes Prevention Program (DPP) (it = 5 1). Comparisons were adjusted for age and gender. Results. - In the IFG/IGT subset, significant differences in 1-year changes were observed for systolic blood pressure, which decreased markedly more in the metformin group than in the placebo group (P < 0.003), and for fasting plasma glucose, and total and LDL cholesterol, which decreased slightly in the metformin group, but increased in the placebo group (P < 0.04). Similar results were observed in the subset with DPP criteria. Also, there were no significant differences in 1-year changes for weight, waist-to-hip ratio, 2-h post-load blood glucose, fasting and 2-h post-load insulin, HDL cholesterol, triglycerides and fibrinolytic markers between the two treatment groups. Conclusion. - In subjects at high risk of developing diabetes, the use of metformin showed beneficial and no untoward effects on cardiometabolic risk factors. 050 UR204